Lupus Erythematosus, Systemic Clinical Trials

23 recruitingLast updated: June 18, 2026

There are 23 actively recruiting lupus erythematosus, systemic clinical trials across 41 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Charlotte, North Carolina, United States, São Paulo, Brazil, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Lupus Erythematosus, Systemic Trials at a Glance

23 actively recruiting trials for lupus erythematosus, systemic are listed on ClinicalTrialsFinder across 6 cities in 41 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Charlotte, São Paulo, and Boston. Lead sponsors running lupus erythematosus, systemic studies include AstraZeneca, Chinese SLE Treatment And Research Group, and Viatris Innovation GmbH.

Browse lupus erythematosus, systemic trials by phase

Treatments under study

About Lupus Erythematosus, Systemic Clinical Trials

Looking for clinical trials for Lupus Erythematosus, Systemic? There are currently 23 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lupus Erythematosus, Systemic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lupus Erythematosus, Systemic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 3

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

Lupus Erythematosus, SystemicNephritis, Lupus
Viatris Innovation GmbH300 enrolled11 locationsNCT07201129
Recruiting
Phase 1

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled14 locationsNCT06925542
Recruiting
Phase 4

Trial of Belimumab in Early Lupus

Lupus ErythematosusLupus Erythematosus, Systemic
Northwell Health30 enrolled1 locationNCT03543839
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Lupus Erythematosus, Systemic
AstraZeneca150 enrolled18 locationsNCT06897930
Recruiting
Phase 3

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic
Janssen Research & Development, LLC600 enrolled169 locationsNCT07438496
Recruiting
Phase 2

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

Lupus Erythematosus, SystemicLupus Nephritis
Novartis Pharmaceuticals179 enrolled101 locationsNCT06581198
Recruiting
Phase 2

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Lupus Erythematosus, SystemicLupus Nephritis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company89 enrolled95 locationsNCT07015983
Recruiting

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

Lupus Erythematosus, Systemic
AstraZeneca218 enrolled19 locationsNCT07330245
Recruiting

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic
AstraZeneca100 enrolled11 locationsNCT06673043
Recruiting

NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care

Lupus Erythematosus, Systemic
AstraZeneca125 enrolled16 locationsNCT07424261
Recruiting
Not Applicable

Brief Pain Exposure Therapy (BPET) For Nociplastic Pain

Chronic Low Back Pain (CLBP)FibromyalgiaLupus Erythematosus, Systemic+1 more
University of Michigan125 enrolled1 locationNCT06208514
Recruiting
Not Applicable

Dose Response of Exercise for Arthritis Management

ArthritisGoutRheumatoid Arthritis (RA)+3 more
University of South Carolina285 enrolled1 locationNCT06880653
Recruiting
Phase 3

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic
Viatris Innovation GmbH420 enrolled216 locationsNCT05648500
Recruiting

Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases

Inflammatory Bowel DiseasesArthritis, RheumatoidSjogren's Syndrome+4 more
Centre Hospitalier Régional d'Orléans100 enrolled1 locationNCT06842316
Recruiting

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

Solid TumorsSjogren SyndromeImmune-related Adverse Events+3 more
Hospital Universitario Araba300 enrolled1 locationNCT07249060
Recruiting
Phase 1

Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic
Chinese SLE Treatment And Research Group20 enrolled1 locationNCT06881290
Recruiting
Phase 1Phase 2

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

DermatomyositisPolymyositisANCA-associated Vasculitis+2 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS8 enrolled1 locationNCT06685042
Recruiting

Chinese Rheumatism Biobank(CRB)

Lupus Erythematosus, Systemic
Chinese SLE Treatment And Research Group300 enrolled1 locationNCT06887517
Recruiting
Early Phase 1

Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

Lupus Erythematosus, Systemic
Juventas Cell Therapy Ltd.24 enrolled1 locationNCT06316791
Recruiting

Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)

Lupus Erythematosus, Systemic
University Hospital, Grenoble30 enrolled2 locationsNCT05193591